Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs JD.Com Inc (JD) Price & Performance

Ionis Pharmaceuticals Inc. Common StockTrade
JD.Com IncTrade

Price performance (Past 24H)

Key statistics

Ionis Pharmaceuticals Inc. Common Stock vs JD.Com Inc — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B), while JD.Com Inc trades at $26.62 (market cap $36.51B). The key difference: JD.Com Inc is far larger — about 5.2× Ionis Pharmaceuticals Inc. Common Stock's market cap, and JD.Com Inc pays a 3.73% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and JD.Com Inc for 86 Days on average.

IONSJD
Market Cap
$7.04B$36.51B
Volume
2,977,4408,583,924
Sector
HealthConsumer Cyclical
52-Week High
$86.50$34.53
52-Week Low
$42.38$25.19
Typical Hold Time
0 Days86 Days
Enterprise Value
$6.60B$19.13B
Dividend Yield
—3.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ionis Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

JD.Com Inc

JD.com trades at $26.68, down 0.15% on the day, with a bearish technical signal driven by moving averages. The stock shows strong analyst support with a consensus price target of $35.38 and a 69.57% buy rating. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. Revenue for 2025 reached $1.31 trillion, though net income margin declined to 1.49% from 3.56% in 2024. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, pending EU approval.

JD.com presents a value opportunity with low valuation multiples (P/E of 17.78, P/S of 0.2) and a robust balance sheet featuring $234 billion in cash. However, risks include regulatory scrutiny from EU probes, competitive pressures in Chinese e-commerce, and margin compression. The stock's upside is supported by strong free cash flow and institutional accumulation, but investors must weigh geopolitical and execution risks against the discounted valuation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IONS
100% Buy0% Sell
Avg holding period · 0 Days
JD
61% Buy39% Sell
Avg holding period · 86 Days

About Ionis Pharmaceuticals Inc. Common Stock

Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.

Read more on IONS →

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD →